Dr Ing Hcf Stock EBITDA
| P911 Stock | 58.76 0.06 0.10% |
Dr Ing hcF fundamentals help investors to digest information that contributes to Dr Ing's financial success or failures. It also enables traders to predict the movement of P911 Stock. The fundamental analysis module provides a way to measure Dr Ing's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dr Ing stock.
P911 |
Dr Ing hcF Company EBITDA Analysis
Dr Ing's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Dr Ing EBITDA | 9.38 B |
Most of Dr Ing's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dr Ing hcF is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Dr Ing hcF reported earnings before interest,tax, depreciation and amortization of 9.38 B. This is much higher than that of the Consumer Cyclical sector and 15.79% higher than that of the Auto Manufacturers industry. The ebitda for all Germany stocks is 140.73% lower than that of the firm.
P911 EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dr Ing's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dr Ing could also be used in its relative valuation, which is a method of valuing Dr Ing by comparing valuation metrics of similar companies.Dr Ing is currently under evaluation in ebitda category among its peers.
P911 Fundamentals
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.20 % | |||
| Shares Owned By Insiders | 7.00 % | |||
| Shares Owned By Institutions | 13.64 % | |||
| Revenue | 36.76 B | |||
| Gross Profit | 8.99 B | |||
| EBITDA | 9.38 B | |||
| Book Value Per Share | 251.94 X | |||
| Number Of Employees | 36.52 K |
About Dr Ing Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dr Ing hcF's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Ing using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Ing hcF based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in P911 Stock
Dr Ing financial ratios help investors to determine whether P911 Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in P911 with respect to the benefits of owning Dr Ing security.